Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $9.00 target price on the stock.
Kairos Pharma Price Performance
About Kairos Pharma
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
See Also
- Five stocks we like better than Kairos Pharma
- Where Do I Find 52-Week Highs and Lows?
- Mobileye’s High Short Interest Signals Squeeze Potential
- How to Read Stock Charts for Beginners
- Rivian: Weathering the Storm, Poised for Growth?
- What is MarketRank™? How to Use it
- Avient Stock: Manufacturing Play With Double-Digit Upside
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
